Post-traumatic Stress Disorder Treatment Market, by Drug Type (Antidepressants, Monoamine Oxidase, Antipsychotics or Second generation Antipsychotics, Beta-blockers, Benzodiazepines, and Others), by End user (Adult and Children), by Distribution Channel (

Post-traumatic Stress Disorder Treatment Market, by Drug Type (Antidepressants, Monoamine Oxidase, Antipsychotics or Second generation Antipsychotics, Beta-blockers, Benzodiazepines, and Others), by End user (Adult and Children), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Post-traumatic stress disorder (PTSD) is a psychiatric condition that may occur in people who have witnessed a traumatic shock like natural disaster, a life threatening event, car accident, sexual abuse etc. Symptoms of PTSD may generate after three months or even after a year. Most of the patients suffering from PTSD show symptoms like intrusive memories, avoidance, negative changes in thinking and changes in emotional and physical reactions. For instance, sudden death of a loved one may cause PTSD in some people. People with PTSD have heightened sense of danger. According to the U.S. National centre for PTSD, it is estimated that about 15% of the veterans of Vietnam War and 12% of gulf war veterans have PTSD. According to American Psychiatric Association, women are twice likely to get PTSD as compared to men. Commonly prescribed drugs for post trauma stress disorder includes antidepressants, sertraline, fluoxetine, paroxetine, and others.
Market Dynamics
The increasing number of PTSD suffering adults and teenagers across the globe is expected to drive growth of the PTSD treatment market during the forecast period. For instance, according to the U.S. Department of Veterans Affairs, about 8 million of adults who have gone gone through trauma suffer from PTSD every year. About 10% of women are found to develop PTSD sometime in their life whereas 4% men suffer from PTSD in U.S.
Lack of awareness about the post-traumatic stress disorder can resist the growth of global post-traumatic stress disorder treatment market. High cost of treatment is also a major restrain for the growth of post-traumatic stress disorder treatment market. For instance, according to the report published in the journal of Clinical Psychiatry in 2014, the cost of treatment of PTSD ranges from US$ 1,622 to US$ 4,652 per person every year in the U.S. Thus, these factors are expected to restrain the growth of global post-traumatic stress disorder treatment market.
Key features of the study:
This report provides in-depth analysis of the global post-traumatic stress disorder treatment market, its market size (US$ 990.7 Mn), and its compound annual growth rate (CAGR) 4.2% for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players
It profiles key players in the global post-traumatic stress disorder treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
Key players covered as a part of this study are Allergan PLC, AstraZeneca, Eli Lilly and Company, GlaxoSmithKline PLC, Sun Pharmaceuticals Pvt Ltd, Bristol-Myers Squibb, Johnson and Johnson, Pfizer Inc., Aurobindo Pharma., Amneal Pharmaceuticals LLC, Apotex Inc., Teva Pharmaceuticals Industries Ltd., Mylan N.V., and Bausch Health Companies Inc.
Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
The global post-traumatic stress disorder treatment market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for post-traumatic stress disorder market, research and consulting firms, new entrants, and financial analysts.

Detailed Segmentation:
Global Post-traumatic Stress Disorder Treatment Market, By Drug Type:
Antidepressants
Monoamine Oxidase
Antipsychotics or Second generation Antipsychotics
Beta-blockers
Benzodiazepines
Others
Global Post-traumatic Stress Disorder Treatment Market, By Application:
Adult
Children
Global Post-traumatic Stress Disorder Treatment Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Post-traumatic Stress Disorder Treatment Market, By Region:
North America
By Country:
U.S.
Canada
By Drug Type:
Antidepressants
Monoamine Oxidase
Antipsychotics or Second generation Antipsychotics
Beta-blockers
Benzodiazepines
Others
By Application:
Adult
Children
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Europe
By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
By Drug Type:
Antidepressants
Monoamine Oxidase
Antipsychotics or Second generation Antipsychotics
Beta-blockers
Benzodiazepines
Others
By Application:
Adult
Children
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Asia Pacific
By Country:
Australia
India
China
Japan
ASEAN
South Korea
Rest of Asia Pacific
By Drug Type:
Antidepressants
Monoamine Oxidase
Antipsychotics or Second generation Antipsychotics
Beta-blockers
Benzodiazepines
Others
By Application:
Adult
Children
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Latin America
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
By Drug Type:
Antidepressants
Monoamine Oxidase
Antipsychotics or Second generation Antipsychotics
Beta-blockers
Benzodiazepines
Others
By Application:
Adult
Children
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Middle East
By Country:
GCC
Israel
Rest of Middle East
By Drug Type:
Antidepressants
Monoamine Oxidase
Antipsychotics or Second generation Antipsychotics
Beta-blockers
Benzodiazepines
Others
By Application:
Adult
Children
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Africa
By Country/Region:
South Africa
Central Africa
North Africa
By Drug Type:
Antidepressants
Monoamine Oxidase
Antipsychotics or Second generation Antipsychotics
Beta-blockers
Benzodiazepines
Others
By Application:
Adult
Children
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Company Profiles
Allergan PLC*
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
AstraZeneca
Eli Lilly and Company
GlaxoSmithKline PLC
Sun Pharmaceuticals Pvt Ltd
Bristol-Myers Squibb
Johnson and Johnson
Pfizer Inc.
Aurobindo Pharma.
Amneal Pharmaceuticals LLC
Apotex Inc.
Teva Pharmaceuticals Industries Ltd.
Mylan Pharmaceuticals
Bausch Health Companies Inc.
“*” marked represents similar segmentation in other categories in the respective section.